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Abstract
Background: Continuous subcutaneous infusions (CSCIs) are commonly used in the United Kingdom as a way of
administering medication to patients requiring symptom control when the oral route is compromised. These
infusions are typically administered over 24 h due to currently available safety data. The ability to deliver prescribed
medication by CSCI over 48 h may have numerous benefits in both patient care and health service resource
utilisation. This service evaluation aims to identify the frequency at which CSCI prescriptions are altered at NHS
Acute Hospitals.
Methods: Pharmacists or members of palliative care teams at seven acute NHS hospitals recorded anonymised
prescription data relating to the drug combination(s), doses, diluent and compatibility of CSCIs containing two or
more drugs on a daily basis for a minimum of 2 days, to a maximum of 7 days.
Results: A total of 1301 prescriptions from 288 patients were recorded across the seven sites, yielding 584 discrete
drug combinations. Of the 584 combinations, 91% (n = 533) included an opioid. The 10 most-common CSCI drug
combinations represented 37% of the combinations recorded. Median duration of an unchanged CSCI prescription
across all sites was 2 days.
Conclusion: Data suggests medication delivered by CSCI over 48 h may be a viable option. Before a clinical
feasibility study can be undertaken, a pharmacoeconomic assessment and robust chemical and microbiological
stability data will be required, as will the assessment of the perceptions from clinical staff, patients and their families
on the acceptability of such a change in practice.
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Background
With a recent investigation discovering that one-third of
all patients in UK District General Hospitals are ex-
pected to be in the last year of life [1], and the projected
rise in deaths per year from 468,875 (2014) to 561,000
(2035/36) [2] the challenge of providing adequate end-of
life care is daunting. Additionally, with the majority of
patients expressing a preference to die at home [3, 4],
NHS resources will be placed under increasing pressure
to meet the needs of chronically ill patients who live,
and want to die, in their usual place of residence [5, 6].
NHS England has predicted the need to find £22 bil-
lion worth of savings to balance its books by 2020 [7].
As a result, new ways of providing and structuring ser-
vices are required to optimise care for patients and make
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best use of available resources [8]. These pressures, com-
bined with the large number of unfilled medical and
nursing posts [9], coupled with the falling number of
qualified district nurses (who provide care to patients in
their own homes) [10] mean that changes will be re-
quired to ensure treatment continues to be provided to
the best standard possible.
Continuous subcutaneous infusions (CSCIs) represent
an effective method of multiple drug administration in
end of life care when the oral route is compromised [11,
12]. Available chemical and microbiological stability data
limit the infusion time of a CSCI to a maximum of 24 h
[13]. A pilot study conducted at a large UK teaching
hospital revealed that in 72% (n = 38) of cases, no medi-
cation changes were made to the CSCI within the first
48 h of use [14]. This suggests that in certain circum-
stances (such as patients with stable palliative care
needs), there may be an opportunity to deliver medica-
tion over 48 h. Such practice may have numerous bene-
fits in both patient care (improving patient autonomy/
freedom, enabling clinicians more time to focus on pro-
viding compassionate care) and health service resource
utilisation.
An investigation was undertaken to gather data re-
garding the frequency at which CSCI prescriptions are
altered in Acute NHS Trusts to identify if there may be
a cohort of patients who could theoretically receive a 48-
h CSCI. Secondary outcomes included identifying the
most frequently prescribed drugs and drug combina-
tions, as well as the assessment of doses prescribed.
Methods
An open invitation to participate in this evaluation was
issued via the UK Palliative Care Pharmacist Network;
there were 11 expressions of interest received. Hospital
pharmacists or members of palliative care teams at each
participating site identified patients who were prescribed
CSCIs comprising two or more drugs between July and
December 2016.
A nominated pharmacist from each hospital entered
the data collected into an electronic database maintained
by the Liverpool Cancer Trials Unit. The database was
designed to ensure that no patient information was en-
tered. Data relating to a minimum of 50 patients per site
was targeted; patients who died or were discharged be-
fore 48 h excluded from the study.
Data analysis
For each patient identified, the healthcare practitioner
recorded the drug combination(s), doses, diluent and
compatibility for every CSCI daily, for a minimum of 2
days to a maximum of 7 days. Data collection for each
patient ceased after 7 days’ continuous treatment, or if
the CSCI was discontinued within the 7-day data collec-
tion window.
Of primary interest was the number of days that the
CSCI ran unchanged. Descriptive analyses were per-
formed, with categorical data presented as counts and
continuous data are reported as medians and inter-
quartile ranges. The length of an unchanged CSCI pre-
scription in days was compared, across treatment sites
and the most prevalent drug types, using regression
modelling techniques which account for different levels
of variability between patients and between different
treatment sites.
Results
Of the 11 NHS hospitals who expressed interest, one de-
clined participation, two did not reply to the invitation
and one failed to obtain Research and Development ap-
proval. All sites were in the North of England (Three
hospitals within Merseyside, one hospital each in Lanca-
shire and Greater Manchester with the remainder lo-
cated in South Yorkshire). At the time of data lock,
details from 1301 CSCI prescriptions had been recorded
(1362 entries were recorded, but 61 excluded due to er-
roneous entry), yielding a total of 584 discrete drug
combinations. Water for Injections was used as a diluent
in 766 cases (58.9%), sodium chloride 0.9% as a diluent
in 528 cases (40.6%) and no diluent recorded in 7 cases.
Frequency of prescription changes
An evaluation of the number of days each combination
lasted is included in Table 1 for each site. Two hundred
eighty-eight patients and 582 combinations are included
(2 combinations were removed from this analysis due to
incomplete records). 45% (262/582) were changed within
48 h. 38% (221/582) remained stable over 48 h but were
changed before 72 h. and 17% (99/582) were unchanged
for longer than 3 days. Over a 5-day week (Monday –
Friday), 36.7% (214/582) prescriptions remained un-
changed for 48 h or longer. This increased to 55% (320/
582) when looking at a seven-day week incorporating a
weekend. Overall, median duration of an unchanged
CSCI prescription was 2 days. The median duration of
an unchanged CSCI prescription at sites 3,5, and 7 was,
however, less than 2 days.
Regression modelling was performed to investigate if
there were any differences in the number of days a com-
bination was administered which can be attributed to ei-
ther the site a patient is treated at or any of the drugs
which are administered. Table 2 gives the model esti-
mates for the effects of treatment site. Considering the
different treatment sties, Sites 3, 5 and 7 all had signifi-
cantly negative estimates suggesting that combinations
are generally administered for shorter periods of time at
these sites compared to site 1. Site 4 was also close to
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statistical significance at the 5% level. Results suggest
that the length of time a CSCI were administered were
unaffected by the type of drug that was prescribed.
Drugs used in CSCIs
Table 3 gives the frequency of each drug along with the
mean, median, range and IQR of dose prescribed. The
results show that the four most common drugs (midazo-
lam hydrochloride, oxycodone hydrochloride, levome-
promazine hydrochloride, morphine sulphate) account
for 983/1605 (61%) of all drugs prescribed.
Drug combinations used
Of the 584 drug combinations recorded across the seven
sites, 128 unique drug combinations were identified. The
number of drugs in a combination were distributed as: 2
drugs 251/584 (43%), 3 drugs 232/584 (40%), 4 drugs 98
(17%) and 5 drugs 3 (< 1%). A list of the top 31 drug
combinations prescribed is included in Table 4.
An opioid was included in 91% (n = 533) of cases with
5 of the 6 most common combinations comprising mor-
phine sulphate. The six most common combinations all
comprised midazolam hydrochloride. Twenty-four hour
laboratory-tested chemical compatibility and stability
data at clinically relevant doses were available for 24 of
the top-31 drug combinations [13, 15–25], while 48 h
compatibility and stability data were available for 4 of
the top-31 drug combinations [16, 22–25].
Mean morphine equivalent dose
Table 5 gives the mean daily dose of all opioids pre-
scribed and converts to the equivalent morphine dose as
per current national guidance [27].
Discussion
To our knowledge, this investigation represents the first
analysis of CSCI prescribing trends over a continuous
period of up to 7 days in the United Kingdom. CSCIs
were unchanged following two or more consecutive days
in 55% (n = 320) of cases, compared to 72% (n = 38) in
the pilot study [14]. Of the 320 CSCIs in which drugs or
dosages did not change for periods greater than 2 days,
33% included the days Saturday and Sunday, which are
traditionally less well staffed in NHS establishments.
Despite this, there is a potential population in whom a
48-h CSCI infusion may be practicable both in terms of
decreasing the frequency of interventions administered
to the patient and optimising the utilisation of a health-
care professional’s time.
As demonstrated by the most recent survey of national
CSCI prescribing practice, oxycodone was the most
commonly prescribed opioid identified by this study
[28]. This is despite current national guidance recom-
mending the use of an opioid with the lowest acquisition
cost first-line (currently morphine sulphate) [29]. How-
ever, morphine sulphate is still widely utilised as shown
by its inclusion in five of the six most frequently pre-
scribed drug combinations.
The top two most-common drug combinations corres-
pond with the findings of the most-recent survey of na-
tional prescribing practice. The third most-common
drug combination included the “four core” drugs needed
for quality care of the dying patient (morphine, midazo-
lam, levomepromazine and glycopyrronium) [30]. The
frequency of this prescription, and that its use was re-
stricted to one site (site 7) is anomalous and reasons for
this need investigation in future work. From the clinical






No. of CSCIs ran
unchanged for
one day
No. of CSCIs that
ran unchanged
for 2–3 days
No. of CSCIs that
ran unchanged
for 3+ days
No. of CSCIs that ran for 2 or more





1 83 151 56 57 38 41 2 (1, 4)
2 64 128 48 55 25 28 2 (1, 3)
3 11 20 10 8 2 2 1.5 (1, 2.75)
4 26 53 20 25 8 8 2 (1, 3)
5 34 71 39 26 6 9 1 (1, 2)
6 21 35 12 13 10 9 2 (1, 4)
7 49 124 77 37 10 9 1 (1, 2)
Table 2 Results of the mixed log-logistic model to evaluate
factors associated with administration time
Estimate Standard Error z value Pr(>|z|)
Intercept 1.012 0.098 10.290 0.000
Site 1 – – – –
Site 2 −0.118 0.090 −1.316 0.188
Site 3 −0.372 0.173 −2.152 0.031
Site 4 −0.235 0.123 −1.907 0.057
Site 5 −0.407 0.113 −3.607 0.000
Site 6 0.003 0.135 0.022 0.982
Site 7 −0.437 0.096 −4.549 0.000
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experience of the authors, such patterns can occur with
clinicians that have limited experience of prescribing
CSCI’s. This was also evidenced by frequent, small, in-
cremental dose changes being made to a patient’s CSCI
prescription. The fourth most-common combination
(morphine + midazolam + levomepromazine) as found
by this investigation was sixth most common in the pre-
viously completed evaluation.
Of the top-31 drug combinations, only 4 combinations
have 48-h chemical compatibility and stability data.
However, as 48-h infusions may present a greater patient
infection risk than 24-h infusions, risk/benefit analysis of
ward based CSCI compounding versus pharmacy based
aseptic preparation, or the inclusion of an in-line anti-
microbial filter, [31] will be required prior to adoption
into clinical practice.
While there is potentially an alternative to CSCI pre-
scribing (i.e. utilizing agents that possess long plasma
half-lives (e.g. levomepromazine) or alternative routes of
administration (e.g. transdermal)) these approaches may
not be considered appropriate for several reasons. Firstly,
the administration of large subcutaneous doses of an
agent may result in increased incidents of adverse effects
and injection site irritation. Additionally, the duration of
action of most if not all drugs commonly administered
by CSCI in palliative care does not exceed 24 h. There-
fore, a daily visit will still be required.
Secondly, should a dose need adjusting because, for
example, the patient’s condition changed, with a CSCI
the infusion can be stopped, and doses changed accord-
ingly. In the case of administration of a high dose of a
long-acting drug, or a transdermal preparation, the effect
will persist for a significantly longer duration.
For these reasons, 48-h CSCIs may be preferred due to
the provision of a consistent, drug plasma level.
Strengths and limitations of this investigation
This evaluation was the first of its kind, and as such has
identified opportunities for further research into the util-
ity of extended-duration CSCIs. The adoption of in-
creased infusion duration may have potential to benefit
the utilisation of NHS resources and ultimately patient
care.
Obtaining local Research and Development approvals
at some sites took unexpectedly longer than planned
and as a result limited the volume of data collected. We
were unable to ascertain from all participating sites
whether patients included in the evaluation received a
daily review (and whether such a review was performed
by a specialist or generalist). Additionally, information as
Table 3 Frequency and dose range of drugs prescribed in CSCI combinations recorded









Midazolam hydrochloride Unlicensed 309 11.63 10 (2.5, 60) (5, 12.5)
Oxycodone hydrochloride Licensed 230 21.09 15 (2.5, 150) (7.5, 25)
Levomepromazine hydrochloride Licensed 225 13.77 6.25 (6.2, 150) (6.2, 12.5)
Morphine sulphate Unlicensed 219 19.14 10 (2.5, 190) (7.5, 20)
Glycopyrronium bromide Unlicensed 120 1.35 1.2 (0.4, 2.4) (0.6, 2)
Hyoscine butylbromide Unlicensed 105 89.9 60 (20, 240) (60, 120)
Alfentanil hydrochloride Unlicensed 82 1.8 1.12 (0.2, 12.5) (0.6, 2)
Haloperidol lactate Unlicensed 66 2.7 2.5 (0.5, 10) (1.5, 3)
Cyclizine lactate Unlicensed 62 150 150 (150, 150) (150, 150)
Clonazepam Unlicensed 57 1.18 1 (0.1, 6) (0.2, 2)
Metoclopramide hydrochloride Unlicensed 46 36.52 30 (15, 90) (30, 40)
Ondansetron hydrochloride Unlicensed 33 15.52 12 (8, 36) (12, 16)
Ketamine hydrochloride Unlicensed 13 171.15 150 (100, 300) (125, 200)
Octreotide acetate Unlicensed 11 0.65 0.6 (0.6, 0.9) (0.6, 0.6)
Hyoscine hydrobromide Unlicensed 11 1.47 1.2 (1.2, 2.4) (1.2, 1.5)
Dexamethasone sodium
phosphate
Unlicensed 10 0.98 1 (1, 1) (1, 1)
Levetiracetam Unlicensed 2 375 375 (250, 500) (312.5,
437.5)
Furosemide Unlicensed 2 200 200 (200, 200) (200, 200)
Diamorphine hydrochloride Licensed 2 7.5 7.5 (5, 10) (6.2, 8.8)
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to why the dose remained unchanged following review
by a member of the palliative care team each day was
not recorded. In clinical practice, however, nursing staff
are required to monitor the patient’s symptoms, infusion
device and administration set at frequent intervals
throughout the 24-h infusion period and request a clin-
ical review if the patient’s condition appears to change
significantly. As this evaluation aimed to provide a
“snapshot” of prescribing practice at the participating or-
ganisations, patient demographics were not collected.
Table 4 Top 31 combinations present in 1301 recorded CSCI prescriptions
Drug 1 Drug 2 Drug 3 Drug 4 Frequency
Morphine sulphate Midazolam hydrochloride 40a
Oxycodone hydrochloride Midazolam hydrochloride 35
Morphine sulphate Glycopyrronium bromide Levomepromazine hydrochloride Midazolam hydrochloride 25
Morphine sulphate Levomepromazine hydrochloride Midazolam hydrochloride 22
Oxycodone hydrochloride Hyoscine butylbromide Midazolam hydrochloride 21
Morphine sulphate Glycopyrronium bromide Midazolam hydrochloride 19
Oxycodone hydrochloride Levomepromazine hydrochloride 14
Alfentanil hydrochloride Midazolam hydrochloride 13a
Oxycodone hydrochloride Glycopyrronium bromide Levomepromazine hydrochloride Midazolam hydrochloride 13
Morphine sulphate Levomepromazine hydrochloride 13a
Oxycodone hydrochloride Levomepromazine hydrochloride Midazolam hydrochloride 13
Oxycodone hydrochloride Metoclopramide hydrochloride 10
Oxycodone hydrochloride Clonazepam Haloperidol lactate 10
Oxycodone hydrochloride Clonazepam 10
Oxycodone hydrochloride Cyclizine lactate 10
Alfentanil hydrochloride Glycopyrronium bromide Levomepromazine hydrochloride Midazolam hydrochloride 10
Morphine sulphate Cyclizine lactate 9
Oxycodone hydrochloride Hyoscine butylbromide Haloperidol lactate 8
Morphine sulphate Hyoscine butylbromide Midazolam hydrochloride 8
Morphine sulphate Metoclopramide hydrochloride 7a
Oxycodone hydrochloride Haloperidol lactate Midazolam hydrochloride 7
Alfentanil hydrochloride Levomepromazine hydrochloride Midazolam hydrochloride 7
Hyoscine butylbromide Levomepromazine hydrochloride 7
Oxycodone hydrochloride Glycopyrronium bromide Midazolam hydrochloride 7
Glycopyrronium bromide Midazolam hydrochloride 7
Oxycodone hydrochloride Cyclizine lactate Haloperidol lactate 6
Alfentanil hydrochloride Glycopyrronium bromide Midazolam hydrochloride 6
Alfentanil hydrochloride Hyoscine butylbromide Levomepromazine hydrochloride Midazolam hydrochloride 5
Morphine sulphate Hyoscine butylbromide Levomepromazine hydrochloride Midazolam hydrochloride 5
Oxycodone hydrochloride Hyoscine butylbromide Levomepromazine hydrochloride Midazolam hydrochloride 5
Oxycodone hydrochloride Hyoscine butylbromide Levomepromazine hydrochloride 5
aindicates combinations known to have been analysed for 48-h compatibility and stability at clinically relevant doses
Table 5 Mean morphine equivalent daily dose for prescribed opioids
Opioid Mean parenteral daily dose (mg) Mean oral morphine equivalent dose (mg)
Alfentanil hydrochloride 1.8 54
Diamorphine hydrochloride 7.5 22.5
Morphine sulphate 19.14 38.28
Oxycodone hydrochloride 21.09 84.36
N.B Current evidence suggests that doses of parenteral morphine and parenteral oxycodone are equivalent (i.e. 1:1) [26]
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Should a national registry be developed, these details
would be captured and allow identification of specific
patient groups more likely to receive benefit from this
intervention.
A further limitation of this investigation was that all
acute hospitals that took part were based in the North of
England, with a particular focus on the North-West and
only performed within an acute hospital setting.
Conclusions
This evaluation identified patients receiving treatment
by a CSCI who did not require changes to drugs and/or
dosages for at least 48 h. Thus, there may be a cohort of
patients in whom there is the potential to extend the in-
fusion period from the current standard of 24 h to 48 h.
Future implications for research
To confirm this articles findings and explore populations
in which such an intervention may be beneficial, a more
robust assessment of practice is required. For example, a
future study should also investigate the prescribing of
CSCIs in primary care to determine if this follows a
similar pattern to that observed in this evaluation. To
this end, the creation of a national registry of both pri-
mary and secondary care CSCI prescribing may assist in
helping to explore the points previously mentioned and
identify suitable patient cohorts.
Prior to the undertaking of any clinical feasibility
study, pharmacoeconomic analysis and robust chemical
and microbiology stability data would be required for all
commonly encountered drug combinations. Ideally, such
a study would incorporate assessment of the perceptions
of clinical staff, patients and their families on the accept-
ability of such a fundamental change in practice.
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